CAR-T cells targeting IL-1RAP for high-risk MDS
Part of Blood & lymphatic clinical trials.
This trial tests a new therapy using your own immune cells (CAR-T cells) that are engineered to target a protein called IL-1RAP on MDS cells. It may be an option for people with high-risk MDS or low-risk MDS with certain poor features, especially if standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of myelodysplastic syndrome (MDS).
- Your MDS should be either low-risk with specific poor features (like 5-19% blasts in the marrow or bad genetic changes) or high-risk based on the IPSS-M scoring system.
- You may be newly diagnosed, or your MDS has come back or not responded to common treatments (like Vidaza, Dacogen, or a stem cell transplant).
- You cannot have another active cancer (like a solid tumor or leukemia) that is being treated.
- You must be able to have a bone marrow biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
This trial tests a new treatment called CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatments. CAR-T cells are specially designed to find and destroy cancer cells. The goal is to see if this therapy is safe and works for patients whose cancer cells have specific markers (CD33, CD123, or CLL-1).
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Hear when a new Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.